Storgate LLC Buys New Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Posted by Brenda Bartman on Jun 13th, 2026

Storgate LLC bought a new stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 21,948 shares of the company’s stock, valued at approximately $685,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Public Sector Pension Investment Board lifted its stake in shares of Teva Pharmaceutical Industries by 11.5% during the third quarter. Public Sector Pension Investment Board now owns 670,467 shares of the company’s stock worth $13,543,000 after purchasing an additional 69,000 shares in the last quarter. Menora Mivtachim Holdings LTD. lifted its stake in shares of Teva Pharmaceutical Industries by 1.1% during the third quarter. Menora Mivtachim Holdings LTD. now owns 38,920,294 shares of the company’s stock worth $786,190,000 after purchasing an additional 427,000 shares in the last quarter. Victory Capital Management Inc. lifted its stake in shares of Teva Pharmaceutical Industries by 2.0% during the third quarter. Victory Capital Management Inc. now owns 2,360,762 shares of the company’s stock worth $47,687,000 after purchasing an additional 45,395 shares in the last quarter. WealthTrust Asset Management LLC acquired a new position in shares of Teva Pharmaceutical Industries during the third quarter worth about $856,000. Finally, Hudson Bay Capital Management LP lifted its stake in shares of Teva Pharmaceutical Industries by 87.5% during the third quarter. Hudson Bay Capital Management LP now owns 225,000 shares of the company’s stock worth $4,545,000 after purchasing an additional 105,000 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Up 0.0%

NYSE:TEVA opened at $34.58 on Friday. The company has a debt-to-equity ratio of 1.70, a quick ratio of 0.78 and a current ratio of 1.01. Teva Pharmaceutical Industries Ltd. has a one year low of $14.99 and a one year high of $37.35. The business’s 50-day simple moving average is $33.28 and its 200 day simple moving average is $31.96. The stock has a market cap of $39.75 billion, a price-to-earnings ratio of 26.00, a price-to-earnings-growth ratio of 3.53 and a beta of 0.84.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last released its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The business had revenue of $3.98 billion for the quarter. As a group, sell-side analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.36 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Christine Fox sold 21,258 shares of the business’s stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $35.31, for a total value of $750,619.98. Following the transaction, the executive vice president owned 63,647 shares in the company, valued at approximately $2,247,375.57. The trade was a 25.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Mark Sabag sold 144,180 shares of the business’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $34.99, for a total value of $5,044,858.20. Following the completion of the transaction, the insider owned 80,760 shares in the company, valued at approximately $2,825,792.40. This trade represents a 64.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 421,470 shares of company stock valued at $14,570,945. Insiders own 0.54% of the company’s stock.

Analyst Ratings Changes

TEVA has been the topic of a number of recent research reports. Truist Financial boosted their price objective on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Piper Sandler restated an “overweight” rating and set a $42.00 price objective (up from $41.00) on shares of Teva Pharmaceutical Industries in a research note on Thursday, April 30th. UBS Group boosted their price objective on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. JPMorgan Chase & Co. boosted their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Finally, Wall Street Zen upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Saturday, June 6th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $41.78.

Get Our Latest Stock Report on TEVA

Teva Pharmaceutical Industries Company Profile

(Free Report)

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.